Drug Pricing Scrutiny Could Impact Device Stocks - Merrill Lynch Analyst
This article was originally published in The Gray Sheet
Executive Summary
Stock valuations in the medical device sector may be adversely affected by the threat of federal scrutiny over U.S. prescription drug pricing, given the tendency of some investors to lump devices with drugs when making decisions, according to Merrill Lynch medical device analyst Daniel Lemaitre.